logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

Press Releases

Navigation Toggle Navigation
  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Oct 7, 2022

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

  • Aug 15, 2022

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

  • Jul 28, 2022

PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation

  • Jul 21, 2022

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

  • Jul 19, 2022

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

  • Jul 11, 2022

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

  • Jul 5, 2022

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

  • Jun 15, 2022

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

  • Jun 13, 2022

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

  • Jun 8, 2022

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

RSS
  • 1
  • 2
  • 3
  • Next »

Contact Us

PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada 89169
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan February 2, 2023
  • PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value October 7, 2022